ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) announced the initiation of ENHANCE-1, a Phase III study to evaluate pimavanserin for adjunctive treatment of schizophrenia in patients with …
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) announced the initiation of SERENE, a Phase II study with pimavanserin for the treatment of agitation in patients with Alzheimer’s …
Needham analyst Alan Carr weighs in on ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) after hosting a call last week with key opinion leader (KOL) Dr.
In a research report released today, Roth Capital analyst Michael Higgins resumed coverage on ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) with a Neutral rating on …
By Dana Lyons A key gauge of biotechnology stocks is testing major trendline support presently – can it hold yet again? When this …
Cowen’s biotech team weighs in with upbeat perspectives on biotech firms Gilead Sciences, Inc. (NASDAQ:GILD), Exelixis Inc.
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) has been awarded the California Life Sciences Association’s 2016 Pantheon DiNA Award for Outstanding Therapeutic Product for NUPLAZID™ (pimavanserin), the …
ACADIA Pharmaceuticals Inc.’s (NASDAQ:ACAD) pipeline drug Nuplazid was approved in May to treat Parkinson’s Disease Psychosis (PDP) and launched the following month.
H.C.
Cowen analyst Ritu Baral is out with a positive research note on shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) after hosting a group meeting last …
